|
![]() |
|
|
Diprolene: profile and news
Taro tentatively OK'd for Diprolene Jan 26, 2006 Taro medicated lotion gets tentative OK Jan 26, 2006 Taro Medicated Lotion Gets Tentative OK Jan 26, 2006 Taro Receives Tentative Approval for Augmented Betamethasone ... Jan 26, 2006 Acmemeds.com Improves Itself With 101 New Added Medications Aug 20, 2005 Taro Reports 4th Quarter and Full Year 2004 Results Feb 24, 2005 Acne Treatment and Skin Care a Big Business. Proactiv Solution ... Feb 13, 2005 Other information Indication For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses Pharmacology Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. Mechanism Of Action Betamethasone is a glucocorticoid Receptor Agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. Drug Category Corticosteroid; Glucocorticoids; Anti-inflammatory, steroidal; Immunosuppressant; ATC:A07EA04; ATC:C05AA05; ATC:D07AC01; ATC:D07XC01; ATC:H02AB01; ATC:R01AD06; ATC:R03BA04; ATC:S01BA06; ATC:S01CB04; ATC:S02BA07; ATC:S03BA03 Brand Names/Synonyms Alphatrex; Bebate; Becort; Bedifos; Beta-Methasone; Beta-Methasone Alcohol; Beta-Val; Betacorlan; Betacortril; Betaderm; Betadexamethasone; Betafluorene; Betamamallet; Betametasona [Inn-Spanish]; Betametasone [Dcit]; Betamethasone; Betamethasone Alcohol; Betamethasone Base; Betamethasone Cream; Betamethasone Dipropionate; Betamethasone Sodium Phosphate; Betamethasone Valearate; Betamethasone Valerate; Betamethasone [Usan:Ban:Inn:Jan]; Betamethasonum [Inn-Latin]; Betamethasonvalerat Mikron.; Betamethazone; Betapredol; Betasolon; Betatrex; Betnelan; Betsolan; Celestene; Celestone; Celestone Syrup and Tablets; Cidoten; Dermabet; Desacort-Beta; Diproderm; Diprolene; Diprolene Af; Diprosone; Flubenisolone; HSDB 3015; Hormezon; Lotrisone; Luxiq; Luxiqo; Maxivate; Methazon; Rinderon; Rinderon A; Sch 4831; Uticort; Valisone; Valnac; Visubeta Dosage Forms Syrup; Tablet Absorption Minimal if applied topically Interactions Interactions for Betamethasone: APRD00513_IN,txt Chemical IUPAC Name 9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical Formula C22H29FO5 Half Life 5.6 hours Drug Type Approved Drug # Accession No APRD00513 CAS Registry Number 378-44-9 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |